NEW YORK (GenomeWeb) – Resolution Bioscience said today that it has made an agreement with Leidos Biomedical Research to evaluate Resolution's liquid biopsy technology.
Under the agreement, the Frederick National Laboratory for Cancer Research, which Leidos operates, will begin using Resolution's "ctDx" sequencing chemistries and bioinformatics pipeline as part of its evaluation of various liquid biopsy technologies.
Financial details of the collaboration were not disclosed.
Unlike many other liquid biopsy companies that are advancing blood-based cancer assays through central, CLIA-certified labs, Resolution intends to develop distributable liquid biopsy kits that other labs can run in house.
With this new collaboration agreement, the Frederick National Lab will be the first to adopt the company's ctDx platform, Resolution said, adding that other discussions with contract research organizations, reference labs, and academic institutions are ongoing.
Resolution has also said it plans to validate panels for specific tumor types and pursue US Food and Drug Administration approval of these assays for clinical use.